RARE vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIO
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
Ultragenyx Pharmaceutical vs. Its Competitors
Ultragenyx Pharmaceutical (NASDAQ:RARE) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.
Intra-Cellular Therapies has a net margin of -14.07% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Intra-Cellular Therapies' return on equity of -9.93% beat Ultragenyx Pharmaceutical's return on equity.
Ultragenyx Pharmaceutical presently has a consensus price target of $87.00, indicating a potential upside of 119.64%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Intra-Cellular Therapies.
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Intra-Cellular Therapies has higher revenue and earnings than Ultragenyx Pharmaceutical. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 1 mentions for Intra-Cellular Therapies. Ultragenyx Pharmaceutical's average media sentiment score of 0.90 beat Intra-Cellular Therapies' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.
Ultragenyx Pharmaceutical has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Summary
Ultragenyx Pharmaceutical and Intra-Cellular Therapies tied by winning 8 of the 16 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:RARE) was last updated on 7/8/2025 by MarketBeat.com Staff
